ASCO 2024 | Gene-modified autologous gamma-delta T cells in glioblastoma multiforme
Mina Lobbous, MD, MPH, Case Western Reserve University, Cleveland, OH, discusses the Phase I study (NCT04165941) of INB-200, a gene-modified autologous (γδ) T cell therapy in patients with newly diagnosed glioblastoma multiforme (GBM) receiving maintenance therapy with temozolomide. Despite previous immunotherapy trials failing to improve outcomes for patients with GBM, this study has demonstrated promising results. Notably, the gene-modified γδ T cells were able to identify and kill tumor cells independently of antigen presentation by MHC I molecules, suggesting a novel approach to overcoming one of the key limitations in GBM immunotherapy. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
